Comprehensive Test Requisition Form - Page 1 of 6

Size: px
Start display at page:

Download "Comprehensive Test Requisition Form - Page 1 of 6"

Transcription

1 Comprehesive Requisitio Form - Page 1 of 6 COMPLETE ENTIRE FORM AND SUBMIT PEDIGREE/CLINIC NOTES TO AVOID DELAYS patiet iformatio Name (Last, First, MI) Date of Birth (MM/DD/YY) Date of Death (If applicable) Phoe Number/ Aliso Viejo, CA USA Toll Free: Fax: ambryge.com Address City State Zip Biological Sex F M Ethicity: Africa America Asia Caucasia Hispaic Jewish (Ashkeazi) Portuguese Other: specime iformatio*(for phlebotomy service, select all services you are requestig) Type(s) Blood (EDTA preferred) Saliva Buccal Swab^ DNA Cord Blood** Other**: Persoal history of allogeic boe marrow or peripheral stem cell trasplat Collectio Date Specime ID Medical Record # *Blood or saliva from patiets with active/recet hematological disease will udergo additioal review ad may ot be accepted i some cases. For these, cultured fibroblasts or fresh/fresh froze ormal tissue are preferred. See ambryge.com/specime-requiremets for details. **If submittig Cord Blood or a fetal specime, please see bottom of page 5 for Materal Cell Cotamiatio sample submissio test codes. ^Oly for Fragile X sydrome ad chromosomal microarray Phlebotomy Services Request: Phlebotomy draw Isurace preverificatio first Sed kit to patiet^ ^As the patiet's cliicia, I am uaware of ay potetial for complicatio or difficulty i drawig blood for the listed patiet(s). I uderstad that the phlebotomist has full authority to refuse to draw ay patiet if the safety of the phlebotomist ad/or patiet(s) are i questio. idicatio(s) for testig ICD-10 code(s): Will patiet maagemet be chaged depedig o the test results? Yes No preatal samples oly Sample type: Direct CVS Cultured CVS Cultured amio POC Cultured POC Gestatioal age at sample collectio 0rderig licesed provider/sedig facility (Each listed perso will receive a copy of the report) Facility Name (Facility ) Address City State /Coutry Zip Phoe Orderig Licesed Provider Name (Last, First)() NPI# Phoe Fax/ additioal results recipiets Geetic Couselor or Other Medical Provider Name (Last, First) () Phoe/Fax/ Geetic Couselor or Other Medical Provider Name (Last, First) () Phoe/Fax/ cofirmatio of iformed coset, pre-test geetic couselig, ad medical ecessity for geetic testig The udersiged perso (or represetative thereof) esures he/she is a licesed medical professioal authorized geetic testig ad cofirms that the patiet has give appropriate coset. I cofirm that testig is medically ecessary ad that test results may impact medical maagemet for the patiet. I agree to allow Ambry Geetics to facilitate the provisio of pre-test geetic couselig services by a third party service, Iformed DNA (uless otherwise oted), as required by the patiet s isurace provider (uless this box is checked ). Furthermore, all iformatio o this TRF is true to the best of my kowledge. My sigature applies to the attached letter of medical ecessity. Sigature Required for Processig Medical Professioal Sigature: Date: isurace billig (Iclude copy of both sides of isurace card) Patiet Relatio to Policy Holder? Self Spouse Child Isurace Compay Name ad DOB of Policy Holder (if ot self) Policy # HMO Auth # Out Of Pocket: We will start testig immediately, uless you check the box below. We will attempt to cotact you if your estimated out-ofpocket costs are > USD $100 Do ot start testig util I approve paymet terms regardig estimated out-of-pocket costs Patiet agrees to cotact regardig out-of-pocket amout by: Phoe (icludes texts) - cofirm mobile # Special Billig Notes: istitutioal billig Facility Name Sed ivoice to facility address above Address Cotact Name Phoe Number patiet paymet /Fax (Payable to Ambry Geetics) Credit Card (Call ) Patiet Ackowledgemet: I ackowledge that the iformatio provided by me is true ad correct. For direct isurace billig: I authorize my isurace beefits to be paid directly to Ambry Geetics Corporatio (Ambry), authorize Ambry to release medical iformatio cocerig my testig to my isurer, to be my desigated represetative for purposes of appealig ay deial of beefits as eeded ad to request additioal medical records for this purpose. I uderstad that I am fiacially resposible for ay amouts ot covered by my isurer ad resposible for sedig Ambry moey received from my health isurace compay. For patiet paymet by credit card: I hereby authorize Ambry Geetics Corporatio to bill my credit card as idicated above. I order to expedite cosideratio for eligibility for Ambry s Patiet Assistace Program, please provide the total aual gross household icome: $ ad the umber of family members i the household supported by the listed icome:. I authorize Ambry Geetics Corporatio to verify the above iformatio for the sole purpose of assessig fiacial eed, icludig the right to seek supportig documetatio. for y residets: I am a New York residet ad I give Ambry Geetics permissio to store my sample for loger tha 60 days. NOTE: If left blak, coset is iterpreted as NO. Sigature Required For Isurace/Self-Pay Patiets ad NY Sample Storage Coset: Date:

2 Patiet Name: DOB: Aliso Viejo, CA USA Toll Free: Fax: ambryge.com Comprehesive Requisitio Form - Page 2 of 6 cliical history please attach pedigree /cliical cosultatio otes, if available Birth ad Neoatal History Not Applicable Developmetal History Not Applicable please submit the followig with the trf: 1. Cliic Notes 2. Pedigree 3. Isurace Card Gestatioal age at birth: Birth weight: Head circumferece at birth (if available): Cogeital aomalies, explai: Positive ewbor scree, explai: Seizure History Not Applicable Age at first uprovoked seizure (first seizure without fever or other acute metabolic or structural cause): Seizure types (choose all that apply): Ifatile/epileptic spasms Toic Atoic Are seizures: refractory well-cotrolled Has this patiet bee diagosed with a epilepsy sydrome? yes o ukow Pulmoology History Not Applicable Myocloic Typical absece Atypical absece Geeralized toic cloic Focal seizures If yes, please specify: Developmetal delay: yes o ukow Delay prior to seizure oset: yes o ukow N/A Type of delay (choose all that apply): motor laguage global Itellectual disability: yes o ukow Regressio or plateau: yes o ukow Does patiet meet DSM-V diagostic criteria for a autism spectrum disorder?: yes o ukow Cardiac History Not Applicable Sudde cardiac arrest Y N (if yes): # Episodes: Age first icidet: Sycope Y N If yes, # Episodes: Age first icidet: History of cardiomyopathy Y N Age at dx: Cardiomyopathy type: History of Arrhythmia Y N Age at dx: Arrhythmia type: Cogeital heart defect Positive ewbor scree CBAVD Mecoium ileus Ifectios: Sweat chloride: mmol/l Sweat chloride: < >60 Pacreatic isufficiecy IRT level: Respiratory distress, explai: Respiratory assistace devices: Ultrasoud fidigs: Cacer History Not Applicable previous test history (Please iclude copy of test results if performed at aother laboratory) Other History Not Applicable Hearig problems: Migraie: Visio problems: Psychiatric: Hematological: Suspected geetic coditio: Other cliical fidigs: Cacer/Tumor Age at Dx Pathology ad Other Ifo Brai Breast Type: ER (+) (-) uk PR (+) (-) uk HER2/eu (+) (-) uk 2d primary breast Type: ER (+) (-) uk PR (+) (-) uk HER2/eu (+) (-) uk Colorectal Locatio: Ovaria Fallopia tube Primary peritoeal Melaoma/ski Prostate Gleaso Score: Metastatic: Yes No Uterie Hematologic* Type: Allogeic boe marrow or peripheral stem cell trasplat* Other Cacer Type: GI polyps Adeomatous Other type: Polyp #: Polyp #: *Blood or saliva from patiets with active/recet hematological disease will udergo additioal review ad may ot be accepted i some cases. For these, cultured fibroblasts or fresh/fresh froze ormal tissue are preferred. See ambryge.com/specime-requiremets for details. Previously Detected Alteratio(s): Gee Name: ig Lab: Patiet previously tested at Ambry? Yes No Family previously tested at Ambry? Yes No Name: DOB: Relatio: family history (Completio of this sectio is required for orders icludig paretal samples) Mother - Name: DOB: uaffected affected, list symptoms/dx: Dx age: Father - Name: DOB: uaffected affected, list symptoms/dx: Dx age: Relatio to patiet Materal Pateral Disease Dx age

3 Patiet Name: DOB: Aliso Viejo, CA USA Toll Free: Fax: ambryge.com Comprehesive Requisitio Form - Page 3 of 6 Please check the box ext to the test(s) beig ordered below. All tests iclude gee sequece ad deletio/duplicatio aalyses uless otherwise idicated. If this TRF is set to Ambry without or ahead of the sample, it will be treated as a preverificatio. If test ordered is differet tha the test preverified, we will hoor what is o the TRF order form with the sample. For multiple test orders, testig will be ru cocurretly (multiple tests iitiated at the same time) uless otherwise specified. To order reflexive testig (secod test starts pedig first test outcome), please clearly idicate the order of reflexive tests i the otes sectio or ext to the test check box. For reflex test orders, ay positive fidigs (pathogeic/likely pathogeic) i the first test will be reported out to the cliicia, ad the requested secod test will be caceled; all other fidigs will automatically reflex (icludig VUS). cacer Multi-Gee Orders Select the idicatio for testig: Hereditary polyposis 1 Lych sydrome/hnpcc 2 Hereditary breast ad ovaria cacer 3 ig is cliically idicated for other gee(s): Noe of the above To complete your multi-gee order, please select a test optio to the right. (See supplemetal iformatio o page 6 for details). 1 APC/MUTYH 2 MLH1, MSH2, MSH6, PMS2, EPCAM 3 BRCA1/2 * Required: completed CustomNext-Cacer supplemetal form. ambryge.com/forms Sigle Sydrome Orders BraiTumorNext gee brai tumor test BRCAplus gee breast cacer test BreastNext gee breast cacer test CacerNext gee cacer test CacerNext-Expaded gee cacer test ColoNext gee colorectal cacer test CustomNext-Cacer 9510 up to 81 gee custom test* GYNplus gee ovaria/uterie cacer test MelaomaNext gee melaoma test OvaNext gee ovaria/breast/uterie cacer test PacNext gee pacreatic cacer test Pacreatitis pael gee pacreatitis test PGLNext gee PGL/PCC test ProstateNext gee prostate cacer test RealNext gee real cacer test Name Descriptio Name Descriptio Breast ad/or Ovaria Cacer ATM 9014 Ataxia-telagiectasia BRCA1/ BRCA1/2 Ashkeazi Jewish 3-site mutatio pael BRCA1/2 Ashkeazi Jewish 3-site mutatio pael with reflex to BRCA1/2 aalysis if egative CHEK DICER PALB PTEN 2106 Hereditary breast ad ovaria cacer PTEN-related disorders (icludig Cowde sydrome) TP Li-Fraumei sydrome Edocrie Tumors MEN Multiple edocrie eoplasia type 1 RET gee sequece 2680 Multiple edocrie eoplasia type 2 Gastroitestial Cacer APC 3040 Familial adeomatous polyposis APC ad MUTYH cocurret BMPR1A ad SMAD4 cocurret 8726 Adeomatous polyposis 8604 Juveile polyposis sydrome CDH Hereditary diffuse gastric cacer EPCAM del/dup 8519 Lych sydrome Lych sydrome (cocurret) Lych sydrome (sequetial) 8517 MLH1, MSH2, MSH6, PMS2 + EPCAM del/dup 8515 Step 1: MLH1, MSH2, ad MSH6 + EPCAM del/dup; Step 2: PMS2 Gastroitestial Cacer (Cot.) MLH Lych sydrome MSH2 + EPCAM del/dup 8510 Icludes MSH2 iversio MSH2 iversio 2226 Lych sydrome MSH Lych sydrome MUTYH 4661 MUTYH-associated polyposis PMS Lych sydrome STK Peutz-Jeghers sydrome Geitouriary Cacer BAP FH 6301 Hereditary leiomyomatosis ad real cell cacer FLCN 5921 Birt-Hogg-Dubé sydrome VHL 2606 Vo-Hippel Lidau disease TSC1 ad TSC Tuberous sclerosis complex Ski Cacer/Melaoma CDKN2A ad CDK4 cocurret 4708 Familial atypical multiple mole melaoma (FAMMM) PTCH Gorli sydrome Other Hereditary Cacer ig NF Neurofibromatosis type 1 NF Neurofibromatosis type 2 RB Hereditary retioblastoma SMARCB Schwaomatosis Other Sigle Sydrome Orders Please visit ambryge.com/hereditary-cacer-sigle-gee-tests for details. (s): Gee/ Name(s):

4 Patiet Name: DOB: Aliso Viejo, CA USA Toll Free: Fax: ambryge.com Comprehesive Requisitio Form - Page 4 of 6 cardiology Name Comprehesive Cardiovascular Paels CardioNext 8911 CustomNext-Cardio 9520 Arrhythmia Paels LogQTNext 8890 RhythmNext 8900 CPVTNext 8902 Cardiomyopathy Paels Descriptio 92 gees for hereditary cardiomyopathies ad arrhythmias Up to 167 gees related to hereditary cardiomyopathies, arrhythmias, TAAD, HHT, Nooa, ad lipidemias. Required: completed CustomNext-Cardio supplemetal form. ambryge.com/forms 17 gees for log QT, Brugada ad short QT sydromes 42 gees for log QT sydrome, Brugada ad short QT sydromes, CPVT ad ARVC 4 gees for catecholamiergic polymorphic vetricular tachycardia HCMNext gees for hypertrophic cardiomyopathy HCMNext Reflex 8883 MYBPC3, MYH7 reflex to HCMNext DCMNext gees for dilated cardiomyopathy CMNext gees for hereditary cardiomyopathy ARVCNext 8904 cliical geomics Karyotype 3660 Karyotype, rule out mosaic Hereditary leiomyomatosis real cell carcioma Maturity-oset diabetes of the youg Multiple edocrie eoplasia type I 3662 SNP Array 5490 Familial targeted microarray FH 11 gees for arrhythmogeic right vetricular cardiomyopathy 8310 HNF1A, HNF4A, HNF1B, GCK, PDX MEN1 Chromosome aalysis (requires greetop sodium-hepari tube) Chromosome aalysis (requires greetop sodium-hepari tube) Chromosomal microarray (>2.6 millio copy umber probes ad 750,000 SNP probes) Paid optio. Oly available followig SNP Array (5490) completed at Ambry. Icidetal fidigs urelated to the variat(s) detected i the probad, will NOT be reported. Name of probad tested at Ambry: ExomeNext-Probad 9993 Probad oly exome sequecig edocriology ExomeNext-Probad plus mtdna gastroeterology CFTR gee sequece ad deletio/duplicatio aalysis Hirschsprug disease (RET-related) hematology/ocology 9994 DBANext gees for Diamod-Blackfa aemia DCNext gees for dyskeratosis cogeita multiple cogeital aomalies Probad oly exome sequecig plus mtdna sequecig 1007 Report poly T/TG status 2680 RET gee sequece CHARGE sydrome 2380 CHD7 CdLSNext - Corelia de 7040 NIPBL, SMC1A, HDAC8, RAD21, SMC3 Lage sydrome Name Familial Hypercholesterolemia Multiple edocrie eoplasia type 2 ad familial medullary thyroid cacer (FMTC) Shwachma-Diamod sydrome 2680 RET gee sequece Neurofibromatosis type NF1 PGLNext gee PGL/PCC test vo-hippel Lidau disease 2606 VHL 1440 SBDS Descriptio FHNext gees (APOB, LDLR, LDLRAP1, PCSK9) this box if you would like to have the SLC01B1 c.521t>c polymorphism reported with FHNext, which has bee associated i medical literature with stati-iduced myopathies FCSNext (Familial Chylomicroemia Sydrome) 8920 APOA5, APOC2, GPIHBP1, LMF1, LPL Sitosterolemia 8930 ABCG5, ABCG8 Aeurysms ad Related Disorders TAADNext gees for thoracic aortic aeurysms/dissectios, Marfa sydrome, Ehlers-Dalos ad related disorders Marfa reflex to TAADNext 8783 FBN1 reflex to TAADNext Hereditary Hemorrhagic Telagiectasia (HHT) HHTNext 8672 ACVRL1, ENG, EPHB4, GDF2, RASA1, SMAD4 Nooa Sydrome NooaNext gees for RASopathies Other Trasthyreti amyloidosis 1560 TTR SNP Array* 5490 ExomeNext-Trio 9995 ExomeNext-Trio plus mtdna 9996 ExomeNext-Rapid 9999R Must be ordered through AP* ExomeNext-Select 9500 *AP is AmbryPort, our olie portal ambryge.com/ap Trio exome sequecig Opt-out of Cadidate (ovel) Geetic Etiologies Trio exome sequecig plus mtdna sequecig Opt-out of Cadidate (ovel) Geetic Etiologies Opt-out of Cadidate (ovel) Geetic Etiologies Up to 500 gee custom exome sequecig test If orderig ExomeNext/ExomeNext-Rapid, please complete: Secodary Fidigs Report: below to opt-out of the ACMG Recommeded List of secodary fidigs. If left uchecked, secodary fidigs will be reported. Secodary fidigs are ot available for ExomeNext-Select orders. Opt-out: I choose to declie the ACMG Recommeded List of secodary fidigs Juveile polyposis 8604 BMPR1A, SMAD4 sydrome Pacreatitis 8022 PRSS1, SPINK1, CFTR, CTRC Peutz-Jeghers sydrome 2766 STK11 Chromosomal microarray (>2.6 millio copy umber probes ad 750,000 SNP probes) Nooa sydrome 8402 PTPN11, SOS1, KRAS, RAF1

5 Patiet Name: DOB: Aliso Viejo, CA USA Toll Free: Fax: ambryge.com Comprehesive Requisitio Form - Page 5 of 6 eurology Name Comprehesive Neuro ig CustomNext-Neuro 9540 Epilepsy EpiRapid 7033 EpiRapid reflex to EpilepsyNext 7034 EpiFirst-Fever 7011 EpiFirst-Focal 7017 EpiFirst-IS 7013 EpilepsyNext 7019 Hereditary Neuropathy Migraie pulmoology Familial trasthyreti amyloidosis Familial hemiplegic migraie 1560 TTR 7035 Cogeital Cetral Hypovetilatio Sydrome Cystic Fibrosis Cogeital cetral hypovetilatio sydrome 508 FIRST 1002 rheumatology Descriptio Up to 196 gee custom eurology test. if paretal samples are icluded 16 epilepsy gees with treatmet associatios 16 epilepsy gees with treatmet associatios, reflex to 100 gees for epilepsy 13 gees for febrile seizures if paretal samples are icluded 11 gee for o-lesioal focal epilepsy if paretal samples are icluded 17 gees for ifatile spasms if paretal samples are icluded 100 gees for epilepsy if paretal samples are icluded ATP1A2, CACNA1A, PRRT2, SCN1A if paretal samples are icluded Familial Mediterraea fever 5000 MEFV vascular CFTR gee sequece ad deletio/duplicatio aalysis EDS IV reflex to TAADNext Ehlers-Dalos type IV, vascular type 1580 PHOX2B gee sequece CFTR deltaf508 mutatio aalysis with reflex to CFTR gee sequece ad deletio/duplicatio Report poly T/TG status 1007 Report poly T/TG status 8791 COL3A1 reflex to TAADNext 8790 COL3A1 HHTNext 8672 ACVRL1, ENG, SMAD4, GDF2, RASA1 specific site aalysis (Please iclude a copy of relative's report) Name Neurodevelopmetal Disorders AutismNext 7024 Autism, macrocephaly 2106 PTEN Fragile X sydrome 4544 IDNext 7027 Neurodevelopmet- Expaded 7028 Descriptio Rett sydrome 2026 MECP2 Neurocutaeous/Neuro-Ocology Disorders Ataxia-telagiectasia 9014 ATM 48 gees for sydromic ad o-sydromic autism spectrum disorders if paretal samples are icluded FMR1 repeat expasio aalysis ad methylatio studies 140 gees for sydromic ad o-sydromic itellectual disability if paretal samples are icluded 196 gees for itellectual disability, autism spectrum disorders, ad epilepsy if paretal samples are icluded BraiTumorNext gees for brai tumors HHTNext 8672 ACVRL1, ENG, SMAD4, GDF2, RASA1 Legius sydrome 5724 SPRED1 Li-Fraumei sydrome 2866 TP53 Neurofibromatosis NF1 Neurofibromatosis NF2 Nevoid basal cell carcioma sydrome/ Gorli sydrome 5684 PTCH1 Tuberous sclerosis complex 5904 TSC1, TSC2 vo Hippel-Lidau disease 2606 VHL Marfa sydrome (MFS) MFS reflex to TAADNext 8781 FBN FBN1 reflex to TAADNext TAADNext gees for thoracic aortic aeurysms Gee(s): Mutatio(s): Relative Name: Relatioship to Relative: Accessio # (if tested at Ambry): Positive cotrol sample: will be provided already at Ambry ot available Primary Ciliary Dyskiesia PCDNext 8122 Pulmoary Fibrosis Telomere-related pulmoary fibrosis Respiratory Distress Sydrome Surfactat dysfuctio (respiratory distress sydrome) 21 gees for primary ciliary dyskiesia Report poly T/TG status 8140 TERT, TERC for preatal specimes or cord blood: materal cell cotamiatio (Both test codes required for fetal specimes) 8100 ABCA3, SFTPB, SFTPC gee sequece 1260 MCC for fetal specime or cord blood (ru cocurretly with test) 1262 MCC Referece for materal blood sample (No Charge)

6 Patiet Name: DOB: Aliso Viejo, CA USA Toll Free: Fax: ambryge.com Comprehesive TRF - Hereditary Cacer ig Supplemetal Iformatio - Page 6 of 6 Hereditary Cacer Multi-Gee s Name Gees Adeomatous polyposis 8726 APC, MUTYH BraiTumorNext (27 gees) 8847 AIP, ALK, APC, CDKN1B, CDKN2A, DICER1, MEN1, MLH1, MSH2, MSH6, NBN, NF1, NF2, PHOX2B, PMS2, POT1, PRKAR1A, PTCH1, PTEN, SMARCA4, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL BRCAplus (8 gees) 8836 ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, TP53 BreastNext (17 gees) 8820 ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, TP53 CacerNext (34 gees) 8824 CacerNext-Expaded (67 gees) 8874 APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, BMPR1A, CDH1, CDK4, CDKN2A, CHEK2, DICER1, EPCAM, GREM1, HOXB13, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMAD4, SMARCA4, STK11, TP53 AIP, ALK, APC, ATM, BAP1, BARD1, BLM, BRCA1, BRCA2, BRIP1, BMPR1A, CDH1, CDK4, CDKN1B, CDKN2A,CHEK2, DICER1, EPCAM, FANCC, FH, FLCN, GALNT12, GREM1, HOXB13, MAX, MEN1, MET, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PHOX2B, POT1, PMS2, POLD1, POLE, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, XRCC2 ColoNext (17 gees) 8822 APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53 CustomNext-Cacer (up to 81 gees) Required: complete CustomNext- Cacer supplemetal form. ambryge.com/forms 9510 AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BRCA1, BRCA2, BRIP1, BMPR1A, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CFTR, CHEK2, CPA1, CTNNA1, CTRC, DICER1, EGFR, EPCAM, FANCC, FH, FLCN, GALNT12, GREM1, HOXB13, KIT, MAX, MEN1, MET, MITF, MLH1, MRE11A, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, POT1, PMS2, POLD1, POLE, PRKAR1A, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SPINK1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, XRCC2 GYNplus (13 gees) 8835 BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53 HBOC 8838 BRCA1, BRCA2 Lych sydrome/hnpcc 8517 MLH1, MSH2, MSH6, PMS2 + EPCAM del/dup MelaomaNext (8 gees) 8849 BAP1, BRCA2, CDK4, CDKN2A, MITF, PTEN, RB1, TP53 OvaNext (25 gees) 8830 ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53 PacNext (13 gees) 8042 APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53 Pacreatitis pael (6 gees) 8022 CASR, CFTR, CPA1, PRSS1, SPINK1, CTRC PGLNext (12 gees) 5504 FH, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL ProstateNext (14 gees) 8845 ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, TP53 RealNext (19 gees) 5900 BAP1, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL Updated Orderig Process (as of Jue 8, 2016) We have improved the orderig ad reportig process for our hereditary cacer paels. This helps cofirm that testig for oe or more of the followig gees is cliically idicated: APC, BRCA1, BRCA2, EPCAM, MLH1, MSH2, MSH6, MUTYH, ad PMS2. If you are orderig a multi-gee test, please first select a cliically idicated coditio ad complete your order by selectig a multi-gee order. Please idicate if your patiet meets cliical ad/or isurace testig criteria, or if the testig is otherwise cliically idicated for oe or more of the followig coditios: Adeomatous polyposis (APC/MUTYH) Hereditary breast ad ovaria cacer (BRCA1/2) Lych sydrome/hnpcc (MLH1, MSH2, MSH6, PMS2, EPCAM) If testig is ot cliically idicated for your patiet for ay of the listed optios, please either fill i the other gee(s) optio or select oe of the above. To complete your multi-gee order, please select oe of the appropriate test optios ad/or select other ad eter a appropriate test code(s)/test ame(s). For sigle gee orders, please select the appropriate test optio or eter the gee(s) ad/or test ame(s), as well as the relevat test code i the sigle gee orders sectio. For additioal details about our sigle gee testig optios, please visit ambryge.com/hereditary-cacer-sigle-gee-tests. Example: For a ColoNext multi-gee order, whe Lych testig is cliically idicated for the patiet EXAMPLE _v

Clinical Genomics Test Requisition Form - Page 1 of 5 (Exome Sequencing and Microarray)

Clinical Genomics Test Requisition Form - Page 1 of 5 (Exome Sequencing and Microarray) Cliical Geomics Test Requisitio Form - Page 1 of 5 (Exome Sequecig ad Microarray) COMPLETE ENTIRE FORM TO AVOID DELAYS patiet iformatio Date of Birth (MM/DD/YY) Date of Death (If applicable) Phoe Number/Email

More information

Comprehensive Test Requisition Form - Page 1 of 7

Comprehensive Test Requisition Form - Page 1 of 7 Comprehesive Requisitio Form - Page 1 of 7 COMPLETE ENTIRE FORM TO AVOID DELAYS patiet iformatio Name (Last, First, MI) Date of Birth (MM/DD/YY) Date of Death (If applicable) Phoe Number/Email Aliso Viejo,

More information

Comprehensive Test Menu December 2018

Comprehensive Test Menu December 2018 Comprehensive Test Menu December 2018 Cancer brain tumors Brain tumors, hereditary BrainTumorNext: 27 genes 14-21 days 8847 Neurofibromatosis type 2 (NF2) NF2 14-21 days 9024 Schwannomatosis SMARCB1 14-21

More information

Comprehensive Test Menu August 2018

Comprehensive Test Menu August 2018 Comprehensive Test Menu August 2018 Cancer brain tumors Brain tumors, hereditary BrainTumorNext: 27 genes 14-21 days 8847 Neurofibromatosis type 2 (NF2) NF2 14-21 days 9024 Schwannomatosis SMARCB1 14-21

More information

patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime

More information

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing

More information

Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective

Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families

More information

OncoGeneDx Test Requisition Form

OncoGeneDx Test Requisition Form OncoGeneDx Test Requisition Form Patient Information First name Last name Gender Male Female of birth (mm/dd/yy) Ancestry Caucasian Eastern European Northern European Western European Native American Middle

More information

OncoGeneDx Test Requisition Form

OncoGeneDx Test Requisition Form OncoGeneDx Test Requisition Form Patient Information First name Last name Gender Male Female Date of birth (mm/dd/yy) Ancestry Caucasian Eastern European Northern European Western European Native American

More information

Genetic testing for hereditary cancer

Genetic testing for hereditary cancer Genetic testing for hereditary cancer THE GENETICS OF HEREDITARY CANCER About half of all men and one-third of all women in the US will develop cancer during their lifetimes. Approximately 5% to 10% of

More information

Clinical Cancer Genetics

Clinical Cancer Genetics Clinical Cancer Genetics Lisen Axell, MS, CGC University of Colorado Cancer Center Individuals with cancer Making surgical decisions (lump vs. mast) Making treatment decisions (XRT) Concerns for additional

More information

Genetic Risk Assessment for Cancer

Genetic Risk Assessment for Cancer Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient

More information

Hereditary Cancer. Genetic Testing Services. The GeneDx Experience

Hereditary Cancer. Genetic Testing Services. The GeneDx Experience Hereditary Cancer Genetic Testing Services The GeneDx Experience GeneDx: Where Rare is Common In medical school there is a saying, When you hear hoofbeats, think horses not zebras. Think of common causes

More information

patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime types

More information

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome

More information

The Next Generation of Hereditary Cancer Testing

The Next Generation of Hereditary Cancer Testing The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,

More information

Versus. Cancer genomics Competitive Analysis

Versus. Cancer genomics Competitive Analysis Cancer genomics Competitive Analysis Versus AGH Competitor #1 MYRIAD GENETICS, INC. Headquarters: UT, USA & Switzerland Publicly Traded Company - MYGN Founded: 1992 Company Size: 1001-5000 employees (source:

More information

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome

More information

DNA Genetic Cancer Risk Test. Test Report

DNA Genetic Cancer Risk Test. Test Report Test Report CONTENTS SECTION 1 1-1. Customer Information 1-2. Test Report Summary 1-3. Test Report Details 1-4. List of Cancers / Tumors Tested SECTION 2 2-1. About the Test 2-2. References 1 CL0040-1_B

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Page 1 of 35 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Cancer Susceptibility

More information

A CANCER GENETICIST S (2 ND ) BEST FRIEND IS THEIR PATHOLOGIST. Dr Alan Donaldson Consultant in Clinical Genetics St Michaels Hospital Bristol

A CANCER GENETICIST S (2 ND ) BEST FRIEND IS THEIR PATHOLOGIST. Dr Alan Donaldson Consultant in Clinical Genetics St Michaels Hospital Bristol A CANCER GENETICIST S (2 ND ) BEST FRIEND IS THEIR PATHOLOGIST Dr Alan Donaldson Consultant in Clinical Genetics St Michaels Hospital Bristol Topics to be covered How pathology contributes to genetic diagnosis

More information

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2018 Origination: 7/2013 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Genetic Cancer Susceptibility Panels Using Next Generation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_cancer_susceptibility_panels_using_next_generation_sequencing

More information

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a

More information

Informed Consent Columbia Whole Genome or Whole Exome Sequencing

Informed Consent Columbia Whole Genome or Whole Exome Sequencing Informed Consent Columbia Whole Genome or Whole Exome Sequencing Please read the following form carefully and discuss with your ordering physician before signing consent. This consent is intended for the

More information

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2017 Origination: 7/2013 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City

More information

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins. WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE

More information

MOLECULAR SERVICES. mlabs.umich.edu

MOLECULAR SERVICES. mlabs.umich.edu MOLECULAR SERVICES mlabs.umich.edu 800.862.7284 PICTURED ON LEFT IS MARWAN TAYEH, PH.D, CLINICAL ASSISTANT PROFESSOR, PEDIATRICS - GENETICS, ON RIGHT IS TODD ACKLEY, LABORATORY MANAGER MLabs is a full-service

More information

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins. WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE

More information

BRCAplus. genetic testing for hereditary breast cancer

BRCAplus. genetic testing for hereditary breast cancer BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial

More information

OvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer

OvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer patient guide OvaNext genetic testing for hereditary breast, ovarian, and uterine cancer Because knowing your risk can mean early detection and prevention About half of the women diagnosed with uterine

More information

A guide to genetic testing for hereditary cancers

A guide to genetic testing for hereditary cancers Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions

More information

Diagnostic and Treatment of Patients with Primary and Metastatic Breast Cancer

Diagnostic and Treatment of Patients with Primary and Metastatic Breast Cancer Diagnostic and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Risk and Prevention Breast Cancer Risk and Prevention Versions 2003 2017: Schmutzler / Albert / Blohmer / Fasching

More information

TGL clinical User Guide

TGL clinical User Guide TGL clinical User Guide The Institute of Cancer Research Brookes Lawley Building 15 Cotswold Road Sutton, Surrey SM2 5NG Page 1 of 7 TGL clinical This document describes the services provided by TGL clinical

More information

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6 Page 1 of 6 SHIP TO: Children s Hospital of Philadelphia, Genomic Diagnostic Laboratory, 3615 Civic Center Blvd., Abramson Research Center, 714, Philadelphia, PA 19104-4302 - Phone: (215) 590-4452 Patient

More information

Learn your genetic risk for the most common hereditary cancers.

Learn your genetic risk for the most common hereditary cancers. Learn your genetic risk for the most common hereditary cancers. color.com Color analyzes 30 genes including BRCA1 and BRCA2 to help women and men understand their risk for the most common hereditary cancers,

More information

Populations Interventions Comparators Outcomes Individuals: With a personal and/or family history suggesting an inherited cancer syndrome

Populations Interventions Comparators Outcomes Individuals: With a personal and/or family history suggesting an inherited cancer syndrome Genetic Cancer Susceptibility Panels Using Next- Generation (20493) Medical Benefit Effective Date: 01/01/18 Next Review Date: 09/18 Preauthorization No Review Dates: 09/13, 09/14, 09/15, 09/16, 09/17

More information

Why Test for Hereditary Cancer in Preventive Care?

Why Test for Hereditary Cancer in Preventive Care? Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in

More information

Myriad Financial Assistance Program (MFAP)

Myriad Financial Assistance Program (MFAP) Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.

More information

Genetic Risk Assessment for Cancer

Genetic Risk Assessment for Cancer Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role

More information

patient guide BrainTumorNext genetic testing for hereditary brain tumors Because knowing your risk can mean early detection and prevention

patient guide BrainTumorNext genetic testing for hereditary brain tumors Because knowing your risk can mean early detection and prevention patient guide BrainTumorNext genetic testing for hereditary brain tumors Because knowing your risk can mean early detection and prevention Know the Basics Brain tumors are the most common tumor/cancer

More information

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You? A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is

More information

Are you at risk of Hereditary Cancer? Your Guide to the Answers

Are you at risk of Hereditary Cancer? Your Guide to the Answers Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,

More information

Genetic testing and pancreatic disease

Genetic testing and pancreatic disease Genetic testing and pancreatic disease February 2 d, 2018 Yale Pancreas Symposium 2018: Multidisciplinary Management of Pancreatic Cancer Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director,

More information

patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention

patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention Know the Basics Breast cancer is the most common cancer in women

More information

Genetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017

Genetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017 Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.

More information

The Role of genetic Testing for Inherited Prostate Cancer Risk

The Role of genetic Testing for Inherited Prostate Cancer Risk FOIU July 2018 The Role of genetic Testing for Inherited Prostate Cancer Risk Leonard G. Gomella, MD Chairman, Department of Urology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia,

More information

List of diseases covered by Cancer Predisposition NGS panel

List of diseases covered by Cancer Predisposition NGS panel List of diseases covered by Cancer Predisposition NGS panel Gene Condition AIP Pituitary adenoma 1, multiple types ALK Neuroblastoma, susceptibility to, 3 APC Adenomatous polyposis coli; Colorectal cancer,

More information

MSI positive MSI negative

MSI positive MSI negative Pritchard et al. 2014 Supplementary Figure 1 MSI positive MSI negative Hypermutated Median: 673 Average: 659.2 Non-Hypermutated Median: 37.5 Average: 43.6 Supplementary Figure 1: Somatic Mutation Burden

More information

Germline Testing for Hereditary Cancer with Multigene Panel

Germline Testing for Hereditary Cancer with Multigene Panel Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with

More information

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods:

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: The study listed may iclude approved ad o-approved uses, mulatios or treatmet regimes. The results reported i ay sigle study may ot reflect the overall results obtaied o studies of a product. Bee prescribig

More information

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing. Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing. Hereditary cancer and you Approximately 5% to 10% of all cancers develop because a person inherited a genetic

More information

Outline. Colon Cancer Lynch Syndrome Tumor Testing. Colorectal Cancer. Epidemiology of Colorectal Cancer 9/25/2012 LYNCH SYNDROME REVIEW

Outline. Colon Cancer Lynch Syndrome Tumor Testing. Colorectal Cancer. Epidemiology of Colorectal Cancer 9/25/2012 LYNCH SYNDROME REVIEW Outlie Cacer Lych Sydrome Tumor Testig Daa Zakalik, M.D. Beaumot Cacer Geetics Program OUWB Medical School September 19, 01 Molecular Pathology Symposium Lych sydrome/crc overview Geetics of LS Cliical

More information

Hereditary Cancer Products

Hereditary Cancer Products Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed

More information

GSK Medicine Study Number: Title: Rationale: Study Period: Objectives: Primary Secondary Indication: Study Investigators/Centers: Research Methods

GSK Medicine Study Number: Title: Rationale: Study Period: Objectives: Primary Secondary Indication: Study Investigators/Centers: Research Methods The study listed may iclude approved ad o-approved uses, formulatios or treatmet regimes. The results reported i ay sigle study may ot reflect the overall results obtaied o studies of a product. Before

More information

Simple intervention to improve detection of hepatitis B and hepatitis C in general practice

Simple intervention to improve detection of hepatitis B and hepatitis C in general practice Simple itervetio to improve detectio of hepatitis B ad hepatitis C i geeral practice Zayab al-lami (GP-Birmigham) Co-authors:-Sarah Powell, Sally Bradshaw, Amada Lambert, David Mutimer ad Adrew Rouse Presetatio

More information

Whole Exome Sequencing (WES): Questions and Answers for Providers

Whole Exome Sequencing (WES): Questions and Answers for Providers Whole Exome Sequencing (WES): Questions and Answers for Providers 1. What is Whole Exome Sequencing?... 2 2. What is the difference between Whole Exome Sequencing (WES) and Whole Exome Sequencing Plus

More information

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing. Policy Specific Section: September 27, 2013 January 30, 2015

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing. Policy Specific Section: September 27, 2013 January 30, 2015 Medical Policy Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Type: Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date:

More information

LMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene

LMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene ACTA2* Exon 02-09 NM_001613.2 DSG2* Exon 01-15 NM_001943.3 ACTC1* Exon 01-06 NM_005159.4 DSP* Exon 01-24 NM_004415.2 APC* Exon 01-15

More information

patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention

patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention Know the Basics Risk factors for developing kidney cancer include

More information

Neurological Disorders

Neurological Disorders patient guide Neurological Disorders genetic testing Finding answers quickly to help guide patient care Know the Basics Over 6 million people in the U.S. are affected by a neurological disorder 1-2% of

More information

Enabling Personalized

Enabling Personalized Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development

More information

BioPlex 2200 ToRC IgG and IgM Assays

BioPlex 2200 ToRC IgG and IgM Assays 22 System 22 ad Ig Assays A rapid ad comprehesive testig solutio for ad Ig testig Like No Other The 22 system offers IgG ad Ig assays to simultaeously detect atibodies to T. godii, rubella ad cytomegalovirus

More information

Supplemental Information. Whole-Genome Sequencing. of a Healthy Aging Cohort

Supplemental Information. Whole-Genome Sequencing. of a Healthy Aging Cohort Cell, Volume 165 Supplemental Information Whole-Genome Sequencing of a Healthy Aging Cohort Galina A. Erikson, Dale L. Bodian, Manuel Rueda, Bhuvan Molparia, Erick R. Scott, Ashley A. Scott-Van Zeeland,

More information

Plasma-Seq conducted with blood from male individuals without cancer.

Plasma-Seq conducted with blood from male individuals without cancer. Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer

More information

Understanding Your Positive Result. A guide to understanding your risk and taking action

Understanding Your Positive Result. A guide to understanding your risk and taking action Understanding Your Positive Result A guide to understanding your risk and taking action 2017 Myriad Genetics, Inc. 320 Wakara Way, Salt Lake City, Utah 84108 PH: 1-800-469-7423 FX: 801-584-3615 1 PART

More information

Medical Policy Update

Medical Policy Update Medical Policy Update Summer 2017 Highlights of recent medical policy revisions as well as any new medical policies approved by Prevea360 Health Plan s Medical Policy Committee are shown below. The Medical

More information

patient guide ProstateNext genetic testing for hereditary prostate cancer Because knowing your risk can mean early detection and prevention

patient guide ProstateNext genetic testing for hereditary prostate cancer Because knowing your risk can mean early detection and prevention patient guide ProstateNext genetic testing for hereditary prostate cancer Because knowing your risk can mean early detection and prevention Know the Basics Prostate cancer is the most common cancer in

More information

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK NW Thames Regional Genetics Laboratory Northwick Park Hospital Watford Road Harrow HA1 3UJ United Kingdom Contact: Caroline Sullivan Tel:

More information

Genetics & Precision Medicine Cancer Care

Genetics & Precision Medicine Cancer Care Genetics & Precision Medicine Cancer Care Johnathan M. Lancaster, MD PhD Chief Medical Officer Myriad Genetics Copyright 2015 Myriad Genetics, Inc., all rights reserved. www.myriad.com. Precision Medicine

More information

Pilot and Exploratory Project Support Grant

Pilot and Exploratory Project Support Grant KEY DATES LETTERS OF INTENT DUE November 3, 2014 5:00 pm est FULL PROPOSAL INVITATIONS November 17, 2014 FULL PROPOSAL DEADLINE Jauary 15, 2015 5:00 pm est NOTIFICATION OF AWARDS April, 2015 Pilot ad Exploratory

More information

INFORMATION FOR YOU AND YOUR FAMILY. Melody Transcatheter Pulmonary Valve Therapy

INFORMATION FOR YOU AND YOUR FAMILY. Melody Transcatheter Pulmonary Valve Therapy INFORMATION FOR YOU AND YOUR FAMILY Melody Trascatheter Pulmoary Valve Therapy This booklet is provided to help you ad your loved oes lear more about Melody Trascatheter Pulmoary Valve (TPV) Therapy. Please

More information

Family Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool

Family Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool Besides the BRCA genes, what else to consider in hereditary breast and ovarian cancer? Laurie M. Connors DNP, APNG, FNP-BC, AGN-BC Objectives Evaluate personal & family history to assess risk for hereditary

More information

Health Concerns Overview

Health Concerns Overview F L A M E R E T A R D A N T S V. Health Cocers Overview Edocrie-disruptig chemicals ca mimic estroges (female sex hormoes), adroges (male sex hormoes), ad thyroid hormoes, which ca cotribute to hormoally

More information

Hereditary Cardiovascular Conditions

Hereditary Cardiovascular Conditions patient guide Hereditary Cardiovascular Conditions genetic testing for inherited cardiovascular diseases Finding answers quickly to help guide patient care Know the Basics 34 million people worldwide have

More information

OncoGeneDx Test Requisition Form (River City)

OncoGeneDx Test Requisition Form (River City) OncoGeneDx Test Requisition Form (River City) Patient Information First name Last name Gender Male Female Date of birth (mm/dd/yy) Ancestry Caucasian Eastern European Northern European Western European

More information

Stacy Norman, D.D.S. William A. Stellenwerf, M.S., D.D.S., P.C Timber Shadows Dr., Bldg. A Kingwood, Texas (281)

Stacy Norman, D.D.S. William A. Stellenwerf, M.S., D.D.S., P.C Timber Shadows Dr., Bldg. A Kingwood, Texas (281) Stac Norma, D.D.S. William A. Stellewerf, M.S., D.D.S., P.C. 2325 Timber Shadows Dr., Bldg. A Kigwood, Texas 77339 (281) 359-9100 PERSONAL HISTORY: Date: Name: Birth Date: Sex: Marital Status: Address:

More information

Pilot and Exploratory Project Support Grant

Pilot and Exploratory Project Support Grant KEY DATES LETTERS OF INTENT DUE November 2, 2015 5:00 pm est FULL PROPOSAL INVITATIONS November 16, 2015 FULL PROPOSAL DEADLINE Jauary 15, 2016 5:00 pm est NOTIFICATION OF AWARDS April, 2016 Pilot ad Exploratory

More information

Primary: To assess the change on the subject s quality of life between diagnosis and the first 3 months of treatment.

Primary: To assess the change on the subject s quality of life between diagnosis and the first 3 months of treatment. Study No.: AVO112760 Title: A Observatioal Study To Assess The Burde Of Illess I Prostate Cacer Patiets With Low To Moderate Risk Of Progressio Ratioale: Little data are available o the burde of illess

More information

Retention in HIV care among a commercially insured population,

Retention in HIV care among a commercially insured population, Retetio i HIV care amog a commercially isured populatio, 2006-2012 Kathy Byrd, MD, MPH 10th Iteratioal Coferece o HIV Treatmet ad Prevetio Adherece Jue 28 30, 2015 Natioal Ceter for HIV/AIDS, Viral Hepatitis,

More information

Meningococcal B Prevention Tools for Your Practice

Meningococcal B Prevention Tools for Your Practice Meigococcal B Prevetio Tools for Your Practice NAPNAP MeB Facts for HCPs Fast Facts Although ucommo, MeB is potetially fatal. 1 MeB symptoms progress quickly; death ca occur i 24 hours or less. MeB accouts

More information

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,

More information

Information Following Treatment for Patients with Early Breast Cancer. Bradford Teaching Hospitals. NHS Foundation Trust

Information Following Treatment for Patients with Early Breast Cancer. Bradford Teaching Hospitals. NHS Foundation Trust Iformatio Followig Treatmet for Patiets with Early Breast Cacer Bradford Teachig Hospitals NHS Foudatio Trust What happes ext? You have ow completed your iitial treatmet to remove your breast cacer. There

More information

Hereditary Cancer Update: What do GPOs need to know?

Hereditary Cancer Update: What do GPOs need to know? Hereditary Cancer Update: What do GPOs need to know? Mary McCullum, RN, MSN, CON(C) Nurse Educator, Hereditary Cancer Program BC Cancer Agency October 1, 2016 Conflict of Interest Disclosure Nothing to

More information

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017 Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA

More information

Objectives. Genetics in Cancer Treatment and Prevention. Genes

Objectives. Genetics in Cancer Treatment and Prevention. Genes Objectives Genetics in Cancer Treatment and Prevention Cheryl LaFlore, ARNP, MSN, BC Understand how to integrate genetic and genomic information into oncology nursing practice Define the role of an oncology

More information

PROVIDER POLICIES & PROCEDURES

PROVIDER POLICIES & PROCEDURES PROVIDER POLICIES & PROCEDURES GENETIC CANCER SUSCEPTIBILITY PANELS USING NEXT GENERATION SEQUENCING The purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program

More information

TumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in

TumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in SAMPLE REPORT Ordered By Contact ID:1251298 Example, Doctor, MD MOCKORG44 (10829) 123 Somewhere LaneSuite 4 Heaven NV 78872 US Ph:123-123-1234 Fx:123-123-1223 Org ID:8141 Normal Specimen Accession #: 00-086947

More information

Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer

Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer Supplementary Materials Supplementary

More information

OVARIAN GRANULOSA CELL TUMOR IN A PATIENT WITH A PATHOGENIC VARIANT IN THE CDC73 GENE (HYPERPARATHYROIDISM-JAW TUMOR SYNDROME) MD 1

OVARIAN GRANULOSA CELL TUMOR IN A PATIENT WITH A PATHOGENIC VARIANT IN THE CDC73 GENE (HYPERPARATHYROIDISM-JAW TUMOR SYNDROME) MD 1 AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,

More information

GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics

GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics The Medical/Surgical/Radiation Oncologist s View of Genetics Cancer

More information

The Value of Panel Testing in Inherited Breast Cancer Risk Assessment. Rodney J. Scott Division of Molecular Medicine

The Value of Panel Testing in Inherited Breast Cancer Risk Assessment. Rodney J. Scott Division of Molecular Medicine The Value of Panel Testing in Inherited Breast Cancer Risk Assessment Rodney J. Scott Division of Molecular Medicine Mutation Detection Next Generation DNA sequencing has revolutionised mutation detection

More information

Account # Notes. Physician Name Physician Phone Fax. Diagnosis. CLIA #38D Q11 REQ page 1 of 5

Account # Notes. Physician Name Physician Phone Fax. Diagnosis. CLIA #38D Q11 REQ page 1 of 5 Knight Diagnostic Laboratories Fax: (855) 535-1329 Email: KDLClientServices@ohsu.edu Shipping: 2525 SW 3rd Ave, Ste 350, Portland, OR 97201 Questions? (855) 535-1522 Molecular Genetics Test Requisition

More information

Cancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor

Cancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor Cancer Survivorship Symposium Cancer and Heredity January 16, 2017 Jeanne P. Homer, MS Licensed Certified Genetic Counselor Outline Cancer and Heredity Hereditary Cancer Risk Assessment & Genetic testing

More information

YOUR BEST DAYS START WITH BETTER PROTECTION FROM LOWS. *,1,2

YOUR BEST DAYS START WITH BETTER PROTECTION FROM LOWS. *,1,2 YOUR BEST DAYS START WITH BETTER PROTECTION FROM LOWS. *,1,2 Oly SmartGuard TM from MiiMed takes actio for you whe you eed it most. MiiMed 530G system HIT THE ROAD. WORRY LESS ABOUT GOING LOW. *,1,3 37.5%

More information

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA Comparison of Genomic Coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens Jennifer Hauenstein Oncology

More information